Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
2024-12-12 21:00
Xinhua Silk Road: Pien Tze Huang boosts TCM globalization
2024-12-12 20:43
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
2024-12-12 18:07
KIND Presents Preclinical Results of AND017 in Animal Models of Sickle Cell Disease (SCD), Myelodysplastic Syndromes (MDS), and β-Thalassemia at the 66th American Society of Hematology Meeting and Exposition and Announces FDA Authorization of Investigational New Drug (IND) Application for AND017 for Clinical Trial in Sickle Cell Disease (SCD)
2024-12-12 16:25
RSNA 2024 Spotlight: Careverse Leads the New Trend in Medical AI
2024-12-12 16:04
CBC Group R-Bridge Healthcare Fund Announces up to US$50 Million Financing for Human Investments Ltd. to Fund Motiva® Market Expansion
2024-12-12 14:14
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients
2024-12-12 11:48
Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024
2024-12-12 08:30
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz™
2024-12-11 23:15
Nature Biotechnology | Generative Chemistry Enables Insilico to Develop Gut-Restricted PHD Inhibitors Promising for Intestinal Mucosal Barrier Repair and Immunomodulation
2024-12-11 22:25
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer
2024-12-11 18:05
Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion
2024-12-11 14:44
Call for Application for 2025 Tsinghua Amgen Scholars Program
2024-12-11 14:33
Syrebo Unveils Innovative Rehab Robots at MEDICA 2024: A Spectacular Showcase!
2024-12-11 14:00
Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment
2024-12-11 11:04
Partnership Established to Advance WHO's Road Map for Neglected Tropical Diseases 2021-2030
2024-12-11 09:00
【2024 ASH】TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies
2024-12-10 23:00
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
2024-12-10 22:31
Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety
2024-12-10 22:20
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib
2024-12-10 21:34
1
11
12
13
14
15
981